Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments, argues Prime Therapeutics' Kelly McGrail-Pokuta.
Kelly McGrail-Pokuta
Advertisement
Vice president of trade relations and strategy, chief trade relations officer, Prime Therapeutics
Articles by Kelly McGrail-Pokuta
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Understanding Hemophilia A and B
2
Nonfactor agents for hemophilia prophylaxis: A Q&A with Steven Pipe, M.D.
3
Automated Prior Authorization Speeds Approval of GLP-1 Therapies | AMCP Nexus 2025
4
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations
5
